Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology · 2018
Cited by 229 works. doi:10.1016/j.jtho.2018.02.022 Open-access PDF
Authors
- David Robert Spigel
- Craig H. Reynolds
- David Michael Waterhouse
- Edward B. Garon
- Jason Claud Chandler
- Sunil Babu
- Paul J. Thurmes
- Alexander I. Spira
- Robert M. Jotte
- Jin Zhu
- Wen Hong Lin
- George R. Blumenschein
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
- Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).